The persons entitled to subscribe for the share issue include a few existing shareholders with a long-term engagement for the company, such as the Crafoord family, Segulah Medical Acceleration, Fjärde AP-fonden, Carnegie Fonder, Swedbank Robur Fonder, Fredrik Rapp and Professor Sorin J. Brull, as well as a number of new Swedish and international institutional investors (for example AB Strati).

Through the Share Issue, Senzime will raise a total of approximately SEK 86 million (before transaction costs).

Finance and continue the commercial expansion

Senzime intends to use the net proceeds from the share issue to finance and continue the commercial expansion, secure progress of ongoing innovation projects and finance the company’s working capital needs in line with the expected growth. Furthermore, the share issue will strengthen the shareholder base in the company with additional long-term and strategically important investors, something that the board of directors believes will increase security and stability for the company and its shareholders, it states.

“We’re carrying out a strong and efficient capital raise with the support of long-term new and existing investors. The raise brings us closer to reaching our strategic and financial targets announced in connection with our Q2 report. As a result of our strong sales growth, we also have several long-term loan financing offers on the table that we are evaluating as potential complement. Senzime has a unique market position in a rapidly advancing technology shift, and with our strong balance sheet, we certainly have the prerequisites in place to realize our plans”, says Philip Siberg, CEO of Senzime.